NCT07519811 LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)
| NCT ID | NCT07519811 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Technical University of Munich |
| Condition | Hematologic Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2026-04-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system. When patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it. Patients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version. After reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Inpatient of the Department of Medicine III (Hematology/Oncology) at TUM University Hospital (Klinikum rechts der Isar), Munich, Germany * Receipt of a discharge letter including the sections Current Status, Medical History, Epicrisis, and Further Management as part of routine clinical care * Capacity to provide informed consent * Written informed consent following the consent procedure Exclusion Criteria: * Cognitive impairment precluding independent assessment of comprehension (e.g., dementia, severe encephalopathy) * Participation in another study with potential influence on the study endpoints * Lack of capacity to provide informed consent * Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07519811 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07519811 currently recruiting?
Yes, NCT07519811 is actively recruiting participants. Contact the research team at krischan.braitsch@tum.de for enrollment information.
Where is the NCT07519811 trial being conducted?
This trial is being conducted at Munich, Germany.
Who is sponsoring the NCT07519811 clinical trial?
NCT07519811 is sponsored by Technical University of Munich. The trial plans to enroll 150 participants.